masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration Adenocarcinoma ALK Alleles Anus Autocrine Signaling B-cell lymphoma Biology of neoplasia Biomarker Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder bladder cancer Breast Breast Cancer Carcinoma CD-19 CDKN2A mutation Cells checkpoint inhibitor Checkpoint Inhibitors Circulating miRNAs Clinical Outcome Prediction Colon Colon cancer Colorectal cancer Cord blood buffy coat Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Diagnostic Biomarkers Differential Expression Dissecting Genomic Biomarkers DLBCL Drug Response Efficacy EMT epidemiology outcomes Epstein-Barr Esophageal cancer Expression Profiling Expression profiling Extracted RNA Feasibility FFPE FGF Ligand Trap FGFR Gastrointestinal Cancers Gene expression Gene Expression Comparisons Gene expression profiling Gene Expression Signatures Gene Fusions Gene Signatures Genetic polymorphism Head and Neck Cancer Heart HTG EdgeSeq HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel hypoxia Immune Response Immune-checkpoint blockade Immuno-Oncology Immunotherapy immunotherapy Inflammatory signatures Interferon Gamma Signature Kidney Liposarcoma liquid biopsy Liver Lung Lymphoma Melanoma mesothelioma Metastatic colon cancer Methods Comparison Mice PDX miRNA miRNA WTA Molecular Characterization Mouse mRNA mRNA mRNA custom Multiple myeloma MYC Natural killer cells Neoantigens Non-small cell lung cancer non-small cell lung cancer Novel Therapeutic Targets Oncogenes Oncology-Biomarker Onomirs oral cancer Overexpression P13KmTOR Inhibitor Pancreas pancreatic ductal Pancreatic ductal adenocarcinoma pathology Pathway Analysis Pathways PCA Cell Lines PD-1 PD-L1 Pd-L1 Phase 3 clinical trial PIK3CA mutation Plasma Platform Comparison Predictive Biomarkers Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Prostate qNPA qPCR rectum renal disease Reveal safety Signaling Inhibitors Signaling Pathways Signature Development Signature Validation Skin Small bowel Small Cell Bladder Cancer Small cell bladder cancer Small cell lung cancer Sub-typing System Validation Technology Comparison Tissue-based biomarkers TMB Toxicity TP53 mutation Transplantation Treatment Outcome treatment stratification Triple Negative Breast Cancer Tumor biology Tumor Immunobiology Tumor infiltrating lymphocytes tumor mutational burden type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR WNT Path Signaling Xenograft Tissue

2020

Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.

Naseem, M., et al. Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.

Lenz, A., et al. CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

2019

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.

Download pdf 1.1MB

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.

Battaglin, F., et al. Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2019, Chicago, IL

View External Link

Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).

William, N. W., et al. Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). Presented Clinical Science Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting; June 2, 2019, Chicago, IL. Abstract # 6009

View External Link

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.

Valverde Morales, C. M., et al. Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.  American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL

View External Link

Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab

Hurwitz, M. E., et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL

View External Link

Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis

Srour, M. et al. Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2019 Jun 2, Chicago, IL.

Download pdf 1.2MB
View External Link

Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types.

Szabo, P. M., et al. Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL.

Download pdf 606KB
View External Link

Page last updated February 21, 2020